Abivax SA ADR

Abivax SA ADR represents American depositary shares of Abivax SA, a clinical-stage biotechnology company based in Paris, France. The company focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate and stabilize the immune response in patients with chronic inflammatory diseases. Its work is concentrated in the healthcare sector, particularly biotechnology, with an emphasis on inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Abivax SA’s lead investigational product, obefazimod, is an orally administered small molecule being evaluated in advanced-stage clinical trials for moderately to severely active ulcerative colitis, with additional studies in Crohn’s disease and other immune-mediated indications. By targeting microRNA pathways to regulate inflammation, Abivax SA ADR provides exposure to a specialized segment of the biopharmaceutical industry focused on innovative immune modulation therapies for serious, long-lasting gastrointestinal conditions. Founded in France and operating research facilities and clinical programs in Europe and the United States, the company serves a global market for advanced treatments in immune-mediated diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Marc M. P. de Garidel M.B.A.

Employees

69

Headquarters

Paris, France

Website

www.abivax.com